Navigation Links
Biocon to colloborate for development of Oral peptide drugs for heart diseases.

The Indian Biotech Company, Biocon to colloborate with Nobex Corporation of United States to develop a new oral peptide drug for cardiovascular diseases. The spokesperson of Biocon informed that the company has gone into global research collaboration // on Tuesday for development of peptide based product for treatment of cardiovasculoar diseases. The Biocon press release said, “The collaboration combines the peptide production capabilities of Biocon with the proprietary oral peptide deliver technology of Nobex. Biocon and Nobex plan to advance the oral human brain type natriuretic peptide (hBNP) program towards an Investigational New drug filing with the US food and Drug Administration in 2007 and clinical trials beginning later that year.

“Administration of hBNP by continuous infusion was approved by the FDA in August 200 for the treatment of acute congestive heart failure in the hospital care setting. The intent of an oral hBNP would be to have a product available for chronic use, rather than only for acute use for a number of potential indications, including early stage heart failure patients.’ It said.

“By co-developing a therapeutic product such a oral hBNP of substantial clinical and market value in treating heart failure and other potential cardiovascular indications, we are taking another step towards our innovative product development strategy,” the release quoted Ms Kiran Mazumdar-Shaw, chairman and managing director of Biocon, as sayin.
'"/>




Page: 1

Related medicine news :

1. Biocon To Raise Its Investment In Scotland
2. Biocon To Shift Focus On Innovation To Accelerate Growth
3. Kalam Dedicates New Cancer Drug Developed By Biocon
4. Bayer to Market Biocon Insulin in China
5. Biocon Launches Anti-Cancer Drug
6. Biocon to Launch Anti-arthritis Drug
7. Biocon Unveils Renal Therapies for Kidney Disorders
8. Biocon Net Profit Up by 15 Percent for Fiscal Year
9. Cancer drugs in development nearly doubled since 1995
10. Role of zinc in development
11. Particulate matter affects lung development
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the ... as Vice President of North American Capital Sales at HTG Molecular . ... team in the commercialization of the HTG EdgeSeq system and associated reagents in North ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016   Bay Area Lyme Foundation ... Dean Center for Tick Borne Illness , Harvard ... MIT Hacking Medicine, University of California, Berkeley, and ... the five finalists of Lyme Innovation , ... than 100 scientists, clinicians, researchers, entrepreneurs, and investors ...
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016  American Respiratory ... testing company, is now able to perform sophisticated lung assessments in ... Medical Technologies , Inc. Patients are no longer ... to ndd,s EasyOne PRO ® , ARL patients like Jeanne R. ... testing done in the comfort of her own home. ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, ... less invasive and more durable cerebrospinal fluid treatments, ... funding.  The Series-A funding is led by Innova ... Fund, and other private investors.  Arkis, new financing ... instrumentation and the market release of its in-licensed ...
Breaking Medicine Technology: